Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 3,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin, Computed Tomography, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Glofitamab, Ifosfamide, Lumbar Puncture, Magnetic Resonance Imaging, Methotrexate, Obinutuzumab, Positron Emission Tomography, Prednisone, Rituximab, Rituximab and Hyaluronidase Human, Survey Administration, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Interventions
ACTR087, SEA-BCMA
Biological
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 4 more
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Conditions
B-cell Malignancy, Non-Hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL
Interventions
CTX110
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 18 more
Conditions
Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
IMMU-114
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Newark, Delaware • Savannah, Georgia • Goshen, Indiana + 2 more
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Liposome-encapsulated Daunorubicin-Cytarabine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Ibrutinib
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Tampa, Florida • Philadelphia, Pennsylvania
Conditions
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Conditions
Multiple Myeloma
Interventions
Pembrolizumab, Daratumumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan
Completed Phase 3 Interventional Results available

Aplidin - Dexamethasone in Relapsed/Refractory Myeloma

NCT01102426
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
Plitidepsin, Dexamethasone
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
5
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Jacksonville, Florida + 2 more
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
VV169
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
dasatinib (SPRYCEL), all trans retinoic acid (VESANOID)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Cancer
Interventions
Afuresertib, Carfilzomib
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cary, North Carolina
Conditions
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
Interventions
voruciclib monotherapy, voruciclib and venetoclax
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Duarte, California • Chicago, Illinois • Boston, Massachusetts + 9 more
Conditions
Neuroblastoma, Medulloblastoma, Relapse
Interventions
TPI 287
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
6
States / cities
San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more
Conditions
Hematologic Malignancies, Solid Tumor
Interventions
PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
47
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Conditions
Lymphoma, Large-Cell, Ki-1, Lymphoma, T-Cell
Interventions
UCN-01 (7-hydroxystaurosporine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Myelodysplastic Syndromes
Interventions
Omacetaxine, Azacitidine, G-CSF
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
Interventions
Cytarabine, Filgrastim, Fludarabine, Fludarabine Phosphate, Ivosidenib, Idarubicin
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hodgkin Lymphoma
Interventions
PLX3397
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Rochester, Minnesota + 3 more
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Acute Myeloid Leukemia, AML, Refractory Acute Myeloid Leukemia
Interventions
CRD3874-SI
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
tanespimycin, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

NCT03050216
Conditions
Acute Myeloid Leukemia
Interventions
ALT-803
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota